ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst / Institutional Investors' meet at 4:30 p.m. on Monday, February 1, 2021 for post results [Q3 2020-21] Q&A; session. ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the newspaper cutting dated January 26, 2021 with regard to Notice of Board Meeting of the Company scheduled to be held on Monday, February 1, 2021 published in the Financial Express. ZYDUS WELLNESS LTD.-$ - 531335 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company.
ZYDUS WELLNESS LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2021 ,inter alia, to consider and approve the unaudited financial results for the quarter / nine months ended on December 31, 2020. Zydus' trials of Desidustat shows positive results for Covid-19 management
Clinical, regulatory development of Desidustat in Covid-19 executed in Mexico ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5). ZYDUS WELLNESS LTD.-$ - 531335 - Shareholding for the Period Ended December 31, 2020
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here ZYDUS WELLNESS LTD.-$ - 531335 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Dhanraj DagarDesignation :- Company Secretary and Compliance Officer How Zydus Wellness is trying to regain Complan's lost glory
Tarun Arora, CEO, Zydus Wellness said that the company, to begin with, is investing massively to improve the penetration of the Complan brand in mass markets Zydus gets DCGI nod for conducting phase-3 clinical trials of ZyCoV-D
Company to initiate trials with around 30,000 volunteers 